Vanguard Group Inc. Acquires 125327 Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Vanguard Group Inc. grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% during the third quarter, according to its …

Zynerba Pharmaceuticals logoVanguard Group Inc. grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 651,400 shares of the company’s stock after purchasing an additional 125,327 shares during the quarter. Vanguard Group Inc. owned about 3.69% of Zynerba Pharmaceuticals worth $5,316,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new position in Zynerba Pharmaceuticals in the 3rd quarter worth $612,000. BlackRock Inc. increased its holdings in shares of Zynerba Pharmaceuticals by 25.2% during the 3rd quarter. BlackRock Inc. now owns 298,355 shares of the company’s stock worth $2,435,000 after purchasing an additional 59,998 shares during the period. Engineers Gate Manager LP increased its holdings in shares of Zynerba Pharmaceuticals by 179.8% during the 3rd quarter. Engineers Gate Manager LP now owns 66,270 shares of the company’s stock worth $541,000 after purchasing an additional 42,583 shares during the period. Zeke Capital Advisors LLC bought a new position in shares of Zynerba Pharmaceuticals during the 3rd quarter worth about $193,000. Finally, GSA Capital Partners LLP bought a new position in shares of Zynerba Pharmaceuticals during the 3rd quarter worth about $177,000. Institutional investors and hedge funds own 12.86% of the company’s stock.

Shares of NASDAQ ZYNE traded down $0.07 during trading on Tuesday, reaching $5.65. The company had a trading volume of 460,162 shares, compared to its average volume of 1,087,509. Zynerba Pharmaceuticals Inc has a 52 week low of $2.75 and a 52 week high of $12.50. The company has a market cap of $122.21 million, a PE ratio of -2.16 and a beta of 4.93.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Monday, March 11th. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.21. The company had revenue of $0.09 million during the quarter. As a group, research analysts expect that Zynerba Pharmaceuticals Inc will post -2.1 earnings per share for the current year.

Several research analysts have recently issued reports on ZYNE shares. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 5th. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Saturday, January 19th. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, HC Wainwright restated a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Zynerba Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $14.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Modern Readers and is owned by of Modern Readers. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/03/26/vanguard-group-inc-increases-position-in-zynerba-pharmaceuticals-inc-zyne.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

2 Stocks That Are Just Getting Started: Zynerba Pharmaceuticals, Inc. (ZYNE), Ventas, Inc. (VTR)

That day the Seaport Global Securities set price target on the stock to $16. The stock was given Overweight rating by Cantor Fitzgerald in its report …

The shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been pegged with a rating of Buy by H.C. Wainwright in its latest research note that was published on February 1st, 2018. The research company has also assigned a $23 price target. H.C. Wainwright wasn’t the only research firm that published a report of Zynerba Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Ladenburg Thalmann advised investors in its research note published on January 29th, 2018, to Buy the ZYNE stock while also putting a $25.50 price target. The stock had earned Buy rating from Seaport Global Securities when it published its report on January 26th, 2018. That day the Seaport Global Securities set price target on the stock to $16. The stock was given Overweight rating by Cantor Fitzgerald in its report released on October 2nd, 2017, the day when the price target on the stock was placed at $17. Piper Jaffray was of a view that ZYNE is Overweight in its latest report on September 29th, 2017. ROTH Capital thinks that ZYNE is worth Buy rating. This was contained in the firm’s report on August 15th, 2017.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $16.30. The price of the stock the last time has raised by 102.55% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 63.60.

The shares of the company added by 15.08% during the trading session on Tuesday, reaching a low of $4.92 while ending the day at $5.57. During the trading session, a total of 3.01 million shares were traded which represents a -327991.71% decline from the average session volume which is 917.05K shares. ZYNE had ended its last session trading at 4.84. Zynerba Pharmaceuticals, Inc. currently has a market cap of $115.63M while its P/E earnings growth sits at 1344.57, with a beta of 4.94. Zynerba Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 6.90. ZYNE 52-week low price stands at $2.75 while its 52-week high price is $12.50.

The company in its last quarterly report recorded -$0.44 earnings per share which is above the -$0.65 predicted by most analysts. In the second quarter last year, the firm recorded -$0.47 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -6.82%. Zynerba Pharmaceuticals, Inc. has the potential to record -2.72 EPS for the current fiscal year, according to equities analysts.

Investment analysts at RBC Capital Mkts published a research note on November 2nd, 2018 where it informed investors and clients that Ventas, Inc. (NYSE:VTR) is now rated as Sector Perform. Ladenburg Thalmann also rated VTR as Initiated on January 29th, 2018, with its price target of $42 suggesting that VTR could surge by 0.02% from its current share price. Even though the stock has been trading at $61.51/share, analysts expect it to surge higher by -0.70% to reach $61.09/share. It started the day trading at $61.49 and traded between $60.735 and $61.08 throughout the trading session.

A look at its technical shows that VTR’s 50-day SMA is 62.52 while its 200-day SMA stands at 59.08. The stock has a high of $65.70 for the year while the low is $46.55. The company’s P/E ratio currently sits at 64.50, while the P/B ratio is 2.09. At the moment, only of Ventas, Inc. shares were sold short. The company’s average trading volume currently stands at 2.11M shares, which means that the short-interest ratio is just 2.38 days. Over the past seven days, the company moved, with its shift of -3.74%. Looking further, the stock has dropped -2.37% over the past 90 days while it gained 5.57% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more VTR shares, increasing its portfolio by +0.12% during the last quarter. This move now sees The Vanguard Group Inc purchasing 54,824 shares in the last quarter, thus it now holds 44,647,893 shares of VTR, with a total valuation of $2,801,655,286. BlackRock Fund Advisors meanwhile bought more VTR shares in the recently filed quarter, changing its stake to $1,648,670,534 worth of shares. SSgA Funds Management Inc followed the path by increasing its VTR portfolio by +1.50% in the quarter. This means that SSgA Funds Management Inc bought 311,198 shares in the last quarter and now controls 21,000,958 shares of the VTR stock, with the valuation hitting $1,317,810,115.

Similarly, Fidelity Management Research Co decreased its Ventas, Inc. shares by -4.14% during the recently filed quarter. After selling -467,746 shares in the last quarter, the firm now controls 10,841,701 shares of Ventas, Inc. which are valued at $680,316,738. In the same vein, Cohen Steers Capital Management increased its Ventas, Inc. shares by during the most recent reported quarter. The firm bought 8,876,600 shares during the quarter which increased its stakes to 10,509,102 shares and is now valued at $659,446,151. Following these latest developments, around 0.40% of Ventas, Inc. stocks are owned by institutional investors and hedge funds.

Related Posts:

  • No Related Posts

Zynerba Pharmaceuticals Inc (ZYNE) Shares Bought by Vanguard Group Inc

Vanguard Group Inc grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% in the 3rd quarter, according to the …

Zynerba Pharmaceuticals logoVanguard Group Inc grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 651,400 shares of the company’s stock after buying an additional 125,327 shares during the quarter. Vanguard Group Inc owned 3.69% of Zynerba Pharmaceuticals worth $5,316,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Zynerba Pharmaceuticals by 23.8% in the 3rd quarter. Vanguard Group Inc. now owns 651,400 shares of the company’s stock worth $5,316,000 after buying an additional 125,327 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Zynerba Pharmaceuticals in the 3rd quarter worth about $612,000. Jane Street Group LLC boosted its position in shares of Zynerba Pharmaceuticals by 44.6% in the 3rd quarter. Jane Street Group LLC now owns 35,555 shares of the company’s stock worth $290,000 after buying an additional 10,967 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Zynerba Pharmaceuticals in the 3rd quarter worth about $177,000. Finally, BlackRock Inc. boosted its position in shares of Zynerba Pharmaceuticals by 25.2% in the 3rd quarter. BlackRock Inc. now owns 298,355 shares of the company’s stock worth $2,435,000 after buying an additional 59,998 shares in the last quarter. Institutional investors own 15.32% of the company’s stock.

Several equities research analysts recently commented on the stock. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 5th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, January 27th. Finally, HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $15.88.

ZYNE stock traded up $0.06 during trading on Tuesday, hitting $5.25. The stock had a trading volume of 5,588 shares, compared to its average volume of 1,093,379. Zynerba Pharmaceuticals Inc has a 1-year low of $2.75 and a 1-year high of $12.50. The company has a market capitalization of $91.48 million, a price-to-earnings ratio of -2.17 and a beta of 4.98.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Fairfield Current and is the property of of Fairfield Current. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.fairfieldcurrent.com/news/2019/02/12/zynerba-pharmaceuticals-inc-zyne-shares-bought-by-vanguard-group-inc.html.

Zynerba Pharmaceuticals Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Recommended Story: What are catch-up contributions?

Want to see what other hedge funds are holding ZYNE?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE).

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Rope in Three Stocks: Alteryx, Inc. (NYSE:AYX), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE …

Hot Stocks: AYX, ZYNE, HE are discussed below. Alteryx, Inc. (NYSE:AYX) has became attention seeker from the inquisitor when it experienced a …

Hot Stocks: AYX, ZYNE, HE are discussed below

Alteryx, Inc. (NYSE:AYX) has became attention seeker from the inquisitor when it experienced a change of 5.75%,Whereas, in last 21 trading days was 4.75% and moved up in last 63 trading days of 24.94%. Looking further out we can see that the stock has moved 63.16% over the year to date. Along with these its last twelve month performance is stands at 108.65% while moved 50.47% for the past six months.

Analytical Significance of Simple Moving Average for Alteryx, Inc. (AYX)

The SMA200 of the stock is at 30.15%, SMA20 is -0.60%, while SMA50 is 7.02%.

According to data from FINVIZ’s Research, The price target set for the stock is $44.64 and this sets up an interesting set of potential movement for the stock. The Alteryx, Inc. has Relative Strength Index (RSI 14) of 52.75 along with Average True Range (ATR 14) of 1.98. Its weekly and monthly volatility is 5.56%, 4.21% respectively. The company’s beta value is at N/A.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posting a -3.46% after which it closed the day’ session at $6.42 and the company has experienced volume of 564,099 shares while on average the company has a capacity of trading 385.58K share while its relative trading volume is 1.48. Relative volume is a great indicator to keep a close eye on, but like most indicators it works best in conjunction with other indicators and on different time frames. Higher relative volume you will have more liquidity in the stock which will tighten spreads and allow you to trade with more size without a ton of slippage.

The ZYNE’ Stock performances for weekly, Monthly, Quarterly, half-yearly & year-to-date are mentioned below:-

On a weekly basis, the stock is -16.95%. On a Monthly basis the stock is -33.81%. The quarterly performance for the stock is -37.97%, while the half-yearly performance is -46.90%. Looking further out we can see that the stock has moved -48.72% over the year to date. Zynerba Pharmaceuticals, Inc.’s beta is N/A whilst the stock has an average true range (ATR) of 0.75. Other technical indicators are worth considering in assessing the prospects for ZYNE. RSI for instance is currently at 52.75. The company net profit margin is N/A and gross profit margin is N/A.

ZYNE’s shares were trading -58.82% below from the 52-week high price and 18.45% above from the 52-week price bottom.

Hawaiian Electric Industries, Inc. (NYSE:HE) displayed a change of -0.68% after which it closed the day’ session at $34.93. The overall volume in the last trading session was 474,376 shares.

The HE’s performances for weekly, Monthly, Quarterly, half-yearly & year-to-date are mentioned below:-

On a weekly basis, the stock is 0.52%. On a Monthly basis the stock is 0.14%. The quarterly performance for the stock is 0.81%, while the half-yearly performance is 2.40%. Looking further out we can see that the stock has moved -3.37% over the year to date. Hawaiian Electric Industries, Inc.’s beta is 0.31 whilst the stock has an average true range (ATR) of 0.52. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance is currently at 53.09.

HE’s Performance breakdown (SMA20, SMA50 & SMA200):

Hawaiian Electric Industries, Inc. (NYSE:HE) has seen its SMA20 which is now -0.06%. In looking the SMA 50 we see that the stock has seen a 2.30% while it has a distance of 0.59% from the 200 days simple moving average. The price target set for the stock is $34.20 and this sets up an interesting set of potential movement for the stock, according to data from FINVIZ’s Research.

Related Posts:

  • No Related Posts

Zynerba Pharmaceuticals, Inc. (ZYNE) Stake Increased by Vanguard Group Inc.

Zynerba Pharmaceuticals logo Vanguard Group Inc. increased its holdings in shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) by 12.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 478,763 shares of the company’s …

Zynerba Pharmaceuticals logoVanguard Group Inc. increased its holdings in shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) by 12.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 478,763 shares of the company’s stock after purchasing an additional 52,952 shares during the quarter. Vanguard Group Inc. owned 3.61% of Zynerba Pharmaceuticals worth $8,125,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of ZYNE. Nationwide Fund Advisors acquired a new stake in Zynerba Pharmaceuticals in the second quarter valued at approximately $110,000. New York State Common Retirement Fund acquired a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth approximately $207,000. Rhumbline Advisers acquired a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth approximately $232,000. Bank of New York Mellon Corp grew its position in shares of Zynerba Pharmaceuticals by 5.5% during the first quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock worth $245,000 after buying an additional 635 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth approximately $326,000. 26.95% of the stock is owned by hedge funds and other institutional investors.

In other news, major shareholder Michael Rapp acquired 44,255 shares of the stock in a transaction dated Thursday, October 19th. The shares were acquired at an average cost of $9.59 per share, for a total transaction of $424,405.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.91% of the company’s stock.

A number of research firms have recently weighed in on ZYNE. Canaccord Genuity set a $18.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, December 4th. Zacks Investment Research cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Cantor Fitzgerald set a $17.00 price objective on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 4th. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, November 14th. Finally, Piper Jaffray Companies lifted their target price on Zynerba Pharmaceuticals from $16.00 to $20.00 in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. Zynerba Pharmaceuticals presently has an average rating of “Hold” and an average price target of $15.00.

Shares of Zynerba Pharmaceuticals, Inc. (ZYNE) traded down $0.50 during midday trading on Monday, reaching $11.40. The company’s stock had a trading volume of 371,674 shares, compared to its average volume of 639,093. Zynerba Pharmaceuticals, Inc. has a 52 week low of $5.42 and a 52 week high of $25.95.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.05). During the same quarter last year, the company posted ($0.67) earnings per share. equities analysts anticipate that Zynerba Pharmaceuticals, Inc. will post -2.49 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Zynerba Pharmaceuticals, Inc. (ZYNE) Stake Increased by Vanguard Group Inc.” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/12/11/vanguard-group-inc-raises-holdings-in-zynerba-pharmaceuticals-inc-zyne.html.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts: